Ketamine vs. Antidepressants: A Comprehensive Comparison for Patients

Ketamine and traditional antidepressants treat depression through different biological pathways, and the ketamine vs. antidepressants comparison ultimately comes down to speed, mechanism, cost, and how many medications a patient has already tried without relief. Ketamine, an NMDA receptor antagonist, can ease depressive symptoms within hours. SSRIs and SNRIs, which modulate serotonin and norepinephrine, generally take four to eight weeks to reach full effect. For most patients these are not competing options: ketamine is typically added after multiple antidepressant trials have failed, or used alongside an existing antidepressant rather than replacing it outright. This guide compares mechanism, onset, effectiveness, side effects, cost, and who tends to benefit from each approach, so you can bring informed questions to your prescriber.

How They Work: Mechanisms of Action

Traditional Antidepressants

SSRIs (selective serotonin reuptake inhibitors) like sertraline, fluoxetine, and escitalopram increase the availability of serotonin in the brain. SNRIs (serotonin-norepinephrine reuptake inhibitors) like venlafaxine and duloxetine affect both serotonin and norepinephrine. Other categories, including tricyclics, MAOIs, and atypical antidepressants, target various combinations of neurotransmitters. The common thread is the monoamine hypothesis, the theory that depression results from deficiencies in neurotransmitters such as serotonin, norepinephrine, or dopamine, and that correcting those deficiencies eases symptoms. According to the Mayo Clinic, these medications adjust neurotransmitter levels gradually, which is part of why they typically take four to eight weeks to reach full therapeutic effect.

Ketamine

Ketamine works through a different pathway. It acts primarily as an NMDA receptor antagonist, blocking a type of glutamate receptor in the brain. This triggers a cascade of downstream effects, including increased release of brain-derived neurotrophic factor (BDNF), a protein that supports the growth and survival of neurons, and rapid formation of new synaptic connections. The National Institute of Mental Health notes that this mechanism, often described as promoting neuroplasticity, can produce antidepressant effects within hours of a single ketamine infusion, a timeline that has no precedent among standard antidepressants. The difference in mechanism explains why ketamine can help patients who have not responded to serotonin-based medications: if the underlying problem involves disrupted glutamate signaling rather than a serotonin deficiency, a glutamate-targeting medication may succeed where SSRIs and SNRIs have not.

Speed of Onset

Onset speed is one of the clearest differences between the two approaches and a major reason ketamine has drawn clinical interest for treatment-resistant depression.

Traditional Antidepressants

SSRIs and SNRIs typically require four to eight weeks to reach full therapeutic effect. During this period, patients may experience side effects before they experience benefits, which is difficult for someone already struggling with depression. Some patients need to try multiple medications before finding one that works, a process that can stretch across months. For patients in acute crisis, that timeline can feel unmanageable, and the weeks after starting a medication but before it takes effect are a period of elevated risk.

Ketamine

Ketamine's antidepressant effects can begin within hours to days of the first treatment. In a widely cited study by Berman and colleagues published in Biological Psychiatry, patients with treatment-resistant depression showed significant improvement within four hours of a single IV ketamine infusion. This rapid onset matters most for patients experiencing acute suicidal ideation, where the weeks-long timeline of traditional antidepressants is a serious safety concern; research in the American Journal of Psychiatry found that ketamine can reduce suicidal ideation within 24 hours, a capability no traditional antidepressant can match. The tradeoff is duration: a single ketamine treatment typically produces benefits lasting days to weeks rather than the continuous daily coverage of a standard antidepressant, so sustained improvement requires an initial treatment series followed by periodic maintenance sessions.

Effectiveness and Response Rates

Traditional Antidepressants

According to the STAR*D trial, the largest study of antidepressant effectiveness ever conducted, approximately one-third of patients achieved remission with their first antidepressant. After trying up to four different medications in sequence, the cumulative remission rate reached about 67 percent. For roughly two-thirds of patients with major depression, traditional antidepressants, sometimes after a period of trial and adjustment, provide sufficient relief, which is why they remain the first-line treatment for depression.

Ketamine

For the remaining share of patients, those with treatment-resistant depression who have not responded to at least two adequate antidepressant trials, ketamine offers a documented alternative. Studies consistently report response rates of 60 to 70 percent in this treatment-resistant population, meaning most patients for whom antidepressants have already failed still respond to ketamine. Remission rates, the stricter measure of symptom-free status, are lower with ketamine, typically around 30 to 40 percent after an initial treatment series. Patients who respond without reaching full remission often still experience meaningful improvement in mood, functioning, and quality of life.

Cost and Accessibility

Cost and access are where the two approaches diverge most sharply for most patients. Most SSRIs and SNRIs are available as generics, costing as little as $4 to $30 per month with insurance, and many discount pharmacy programs make them affordable even without coverage. They are prescribed by primary care physicians, psychiatrists, and many nurse practitioners in virtually every community.

Ketamine therapy costs considerably more. IV infusions typically run $400 to $800 per session, and most insurance plans do not cover them. An initial course of 6 infusions can total $2,400 to $4,800, with ongoing maintenance adding thousands more per year. At-home oral ketamine programs delivered through telehealth are generally more affordable, typically $150 to $400 per month, but still cost more than most generic antidepressants. Spravato (esketamine nasal spray) is the ketamine-based option most commonly covered by insurance, but it requires administration at a certified treatment center with a mandatory 2-hour monitoring period. See our full ketamine vs. esketamine comparison for more on how the two forms differ. Ketamine clinics are also concentrated in urban and suburban areas, so patients in rural communities may have few or no local in-person options; telehealth has improved access to oral formulations but cannot prescribe IV or intramuscular ketamine.

Who Tends to Benefit from Each Approach

Traditional antidepressants are typically the appropriate first-line treatment for patients experiencing a first episode of major depression, patients who have not yet tried antidepressant medication, patients who need an affordable long-term option, and patients who respond well to serotonergic or noradrenergic medications. For most people with depression, starting with a traditional antidepressant under the guidance of a knowledgeable prescriber remains the evidence-based standard of care.

Ketamine therapy tends to be the better fit for patients with treatment-resistant depression who have not responded to at least two antidepressant trials, patients in acute crisis or experiencing active suicidal ideation where rapid onset matters, patients who cannot tolerate antidepressant side effects such as sexual dysfunction or weight gain, and patients who have the financial resources and access to pursue treatment. Ketamine is not typically recommended as a first-line treatment; the evidence, cost, and access profile all support trying a traditional antidepressant first for most patients.

Combining Approaches

The two approaches are not mutually exclusive, and many patients use both. A common clinical scenario involves continuing a traditional antidepressant while adding ketamine therapy to address residual symptoms or during a difficult period, with ketamine providing rapid relief while the ongoing antidepressant provides baseline maintenance. Some patients use ketamine as a bridge to rapid stabilization during an acute episode, after which a traditional antidepressant is optimized for long-term management. Others find that the neuroplasticity window ketamine creates helps them respond to antidepressants that had previously been ineffective. Review your full medication list, including any benzodiazepines, with your ketamine provider before starting treatment, since benzodiazepines may reduce ketamine's effectiveness and timing matters.